alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
1... See Tex. R. App. P. 47.4.

COURT OF APPEALS

SECOND DISTRICT OF TEXAS

FORT WORTH

NO. 2-08-266-CR

WILLIAM LESLIE NEAL APPELLANT

V.

THE STATE OF TEXAS STATE

------------

FROM THE 355TH DISTRICT COURT OF HOOD COUNTY

------------

MEMORANDUM OPINION1

------------

A jury convicted Appellant William Leslie Neal of sexual assault and

assault–family violence and assessed his punishment at life imprisonment and

ninety-nine years’ confinement, respectively. The trial court sentenced him

accordingly.
2... Brady v. Maryland, 373 U.S. 83, 83 S. Ct. 1194 (1963).

2

Neal’s court-appointed appellate counsel has filed a motion to withdraw

as counsel and a brief in support of that motion. Counsel’s brief and motion

meet the requirements of Anders v. California by presenting a professional

evaluation of the record demonstrating why there are no arguable grounds for

relief. 386 U.S. 738, 87 S. Ct. 1396 (1967). Neal has filed a pro se brief in

which he enumerates three potential sources of error—ineffective assistance of

counsel, abuses of discretion by the trial court in the admission and exclusion

of evidence and limitations on cross-examination, and alleged Brady2 violations

by the State. 

Once an appellant’s court-appointed attorney files a motion to withdraw

on the ground that the appeal is frivolous and fulfills the requirements of

Anders, this court is obligated to undertake an independent examination of the

record. See Stafford v. State, 813 S.W.2d 503, 511 (Tex. Crim. App. 1991);

Mays v. State, 904 S.W.2d 920, 922–23 (Tex. App.—Fort Worth 1995, no

pet.). Only then may we grant counsel’s motion to withdraw. See Penson v.

Ohio, 488 U.S. 75, 82–83, 109 S. Ct. 346, 351 (1988).

We have carefully reviewed the record, counsel’s brief, Neal’s eightyeight-page pro se brief, and an exhibit admitted solely as an offer of proof. We
3... We note that an ineffective assistance of counsel claim is usually best

addressed by a postconviction writ of habeas corpus. See Thompson v. State,

9 S.W.3d 808, 813–14 & n.6 (Tex. Crim. App. 1999); Ex parte Torres, 943

S.W.2d 469, 475–76 (Tex. Crim. App. 1997); see also Tex. Code Crim. Proc.

Ann. art. 11.07 (Vernon Supp. 2009); Salinas v. State, 163 S.W.3d 734, 740

(Tex. Crim. App. 2005) (“In the majority of cases, the record on direct appeal

is undeveloped and cannot adequately reflect the motives behind trial counsel’s

actions.”).

3

agree with counsel that this appeal is wholly frivolous and without merit; we

find nothing in the record that might arguably support the appeal.3 See Bledsoe

v. State, 178 S.W.3d 824, 827–28 (Tex. Crim. App. 2005); see also Meza v.

State, 206 S.W.3d 684, 685 n.6 (Tex. Crim. App. 2006). Accordingly, we

grant counsel’s motion to withdraw and affirm the trial court’s judgment.

PER CURIAM

PANEL: MCCOY, DAUPHINOT, and GARDNER, JJ.

DO NOT PUBLISH

Tex. R. App. P. 47.2(b)

DELIVERED: December 31, 2009
<table class="regular" id="BLStable_2024_2_23_7_37" style="width: 95%;"><caption><span class="tableTitle">Chart 2c. Seasonal adjustment for Employment Cost Index (ECI) wages and salaries and Current Employment Statistics (CES) average hourly earnings, private industry workers, September, 2014–23</span></caption>
<thead>
<tr>
<th style="vertical-align: middle; min-width: 80px;" rowspan="1" scope="col">Year</th>
<th scope="col">ECI seasonal adjustment</th>
<th scope="col">CES seasonal adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<th scope="row">
<p>2014</p>
</th>
<td>-0.06</td>
<td>0.24</td>
</tr>
<tr class="greenbar">
<th scope="row">
<p>2015</p>
</th>
<td>-0.06</td>
<td>0.24</td>
</tr>
<tr>
<th scope="row">
<p>2016</p>
</th>
<td>-0.08</td>
<td>0.16</td>
</tr>
<tr class="greenbar">
<th scope="row">
<p>2017</p>
</th>
<td>-0.07</td>
<td>0.11</td>
</tr>
<tr>
<th scope="row">
<p>2018</p>
</th>
<td>-0.08</td>
<td>-0.47</td>
</tr>
<tr class="greenbar">
<th scope="row">
<p>2019</p>
</th>
<td>-0.07</td>
<td>-0.46</td>
</tr>
<tr>
<th scope="row">
<p>2020</p>
</th>
<td>-0.07</td>
<td>0.20</td>
</tr>
<tr class="greenbar">
<th scope="row">
<p>2021</p>
</th>
<td>-0.09</td>
<td>0.16</td>
</tr>
<tr>
<th scope="row">
<p>2022</p>
</th>
<td>-0.10</td>
<td>0.15</td>
</tr>
<tr class="greenbar">
<th scope="row">
<p>2023</p>
</th>
<td>-0.10</td>
<td>0.15</td>
</tr>
</tbody>
<tfoot id="BLStable_2024_2_23_7_37_footnotes" style="display: table-footer-group;">
<tr class="footnotes">
<td class="footnotes" colspan="3">
<p>Source: U.S. Bureau of Labor Statistics.</p>
</td>
</tr>
</tfoot>
</table>
2009 Compensation Information for Named Executive Officers



 Exhibit 10.56 
 Named Executive Officer Compensation Information 
 The following table sets forth the annual base salaries for 2008 and 2009
for the “named executive officers” (as defined under applicable securities laws) of Seattle Genetics, Inc. (the “Company”). The table below also sets forth the bonuses awarded to the Company’s named executive officers for
the 2008 fiscal year under the Company’s 2008 Senior Executive Annual Bonus Plan. The 2009 target bonuses (based on a percentage of base salary) for the Company’s named executive officers under the Company’s 2009 Senior Executive
Annual Bonus Plan are also set forth in the table below. 
  

													
	 Name and Title
	  	2008 Base Salary	  	2008 Bonus	  	2009 Base Salary	  	2009 Target Bonus
Percentage	 
	 Clay B. Siegall, Ph.D.
President & Chief Executive Officer
	  	$	575,000	  	$	359,375	  	$	602,350	  	50	%
	 Todd E. Simpson
Chief Financial Officer
	  	$	306,200	  	$	140,852	  	$	313,900	  	40	%
	 Eric L. Dobmeier
Chief Business Officer
	  	$	354,550	  	$	174,439	  	$	370,550	  	40	%
	 Thomas C. Reynolds
Chief Medical Officer
	  	$	352,050	  	$	178,841	  	$	369,700	  	40	%
	 Morris Rosenberg
Executive Vice President, Development
	  	$	300,050	  	$	110,718	  	$	318,300	  	35	%

 Director Compensation Information 
 Please see the section entitled “Director Compensation” in the Company’s 2008 definitive proxy statement on Schedule 14A, filed with
the Securities and Exchange Commission on April 16, 2008, for a description of the compensation provided to members of the Company’s Board of Directors.
```

[Congressional Bills 114th Congress]
[From the U.S. Government Publishing Office]
[S. 681 Introduced in Senate (IS)]

114th CONGRESS
  1st Session
                                 S. 681

To amend title 38, United States Code, to clarify presumptions relating 
 to the exposure of certain veterans who served in the vicinity of the 
              Republic of Vietnam, and for other purposes.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             March 9, 2015

 Mrs. Gillibrand (for herself and Mr. Daines) introduced the following 
 bill; which was read twice and referred to the Committee on Veterans' 
                                Affairs

_______________________________________________________________________

                                 A BILL

 
To amend title 38, United States Code, to clarify presumptions relating 
 to the exposure of certain veterans who served in the vicinity of the 
              Republic of Vietnam, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Blue Water Navy Vietnam Veterans Act 
of 2015''.

SEC. 2. CLARIFICATION OF PRESUMPTIONS OF EXPOSURE FOR VETERANS WHO 
              SERVED IN VICINITY OF REPUBLIC OF VIETNAM.

    (a) Compensation.--Subsections (a)(1) and (f) of section 1116 of 
title 38, United States Code, are amended by inserting ``(including the 
territorial seas of such Republic)'' after ``served in the Republic of 
Vietnam'' each place it appears.
    (b) Health Care.--Section 1710(e)(4) of such title is amended by 
inserting ``(including the territorial seas of such Republic)'' after 
``served on active duty in the Republic of Vietnam''.
    (c) Effective Date.--The amendments made by subsections (a) and (b) 
shall take effect as of September 25, 1985.
                                 <all>
```
Exhibit 11.1

                          MEDIC COMPUTER SYSTEMS, INC.
              COMPUTATIONS OF NET INCOME PER SHARE OF COMMON STOCK


<TABLE>
<CAPTION>

                                                                                   Three Months Ended
                                                                                       March 31,

                                                                                 1997             1996
                                                                                 ----             ----

<S>                                                                          <C>               <C>
Primary:
 Weighted average number of Common Shares outstanding                       24,899,777        24,235,000
 Common Stock equivalents assuming exercise of dilutive options,
    determined by the treasury stock method                                    389,207           547,094
                                                                           ------------------------------

    Common Shares and equivalents                                           25,288,984        24,782,094
                                                                           ==============================

    Net income                                                              $3,116,000        $5,134,000
                                                                           ==============================

    Net income per Common Share                                                  $0.12             $0.21
                                                                           ==============================


Fully Diluted:
 Weighted average number of Common Shares outstanding                       24,899,777        24,235,000
 Common Stock equivalents assuming exercise of dilutive options,
    determined by the treasury stock method                                    389,207           572,500
                                                                           ------------------------------

    Common Shares and equivalents                                           25,288,984        24,807,500
                                                                           ==============================

    Net income                                                              $3,116,000        $5,134,000
                                                                           ==============================

    Net income per Common Share                                                  $0.12             $0.21
                                                                           ==============================


</TABLE>

Note:  The calculation for fully diluted earnings per share has not been
       included with the Consolidated Statements of Operations because fully
       diluted earnings per share does not differ from primary earnings per
       share


                                       17

<PAGE>
#### The People of the State of New York, Respondent, v Jerome Williams, Appellant.

[853 NYS2d 519]

Present-Scudder, EJ., Hurlbutt, Green, Pine and Gorski, JJ.
[DESCRIPTION]Report of 10f-3 Transactions
Securities Purchases in Underwritings Involving
Transactions with Donaldson, Lufkin, & Jenrette Securities Co
Subject to Rule 10f-3 Under the Investment Company Act of 1940
ALLIANCE CONSERVATIVE INVESTORS FUND
<TABLE>
10f-3 TRANSACTIONS FOR THE PERIOD JUNE 1, 1996 THROUGH AUGUST 31, 1996
<CAPTION>
                                                                            Total
                          Date     Shares   % of FundPrice perPurchased by  Issued   Purchased                   Held
Security                  PurchasedPurchasedAssets   Share    Fund Group    (000)    By Group Broker(s)          08/31/96
<C>                       <C>      <C>      <C>      <C>      <C>           <C>      <C>      <C>                <C>
Teleport Communications   06/27/96 900      0.00%    $16.00   567,800       23,500   0.00%    Merrill Lynch      0
</TABLE>
<TABLE>
10f-3 TRANSACTIONS FOR THE PERIOD SEPTEMBER 1, 1996 THROUGH NOVEMBER 30, 1996
<CAPTION>
                                                                            Total
                          Date     Shares   % of FundPrice perPurchased by  Issued   Purchased                   Held
Security                  PurchasedPurchasedAssets   Share    Fund Group    (000)    By Group Broker(s)          11/30/96
<C>                       <C>      <C>      <C>      <C>      <C>           <C>      <C>      <C>                <C>
Crown Cork & Seal, Inc.   10/24/96 1,000    0.10%    $46.25   5,800         23,500   0.02%    Lazard Freres & Co.2,000
Deutsche Telecom          11/18/96 400      0.00%    $18.89   596,900       85,000   0.70%    Goldman Sachs      900
</TABLE>
<TABLE>
10f-3 TRANSACTIONS FOR THE PERIOD DECEMBER 1, 1996 THROUGH FEBRUARY 28, 1997
<CAPTION>
                                                                            Total
                          Date     Shares   % of FundPrice perPurchased by  Issued   Purchased                   Held
Security                  PurchasedPurchasedAssets   Share    Fund Group    (000)    By Group Broker(s)          02/28/97
<C>                       <C>      <C>      <C>      <C>      <C>           <C>      <C>      <C>                <C>
Circuit City (Car Max Grou02/04/97 300      0.01%    $20.00   238,900       21,860   1.09%    Morgan Stanley     2,300
</TABLE>
1-Purchase may not exceed 3% of Fund's Total Assets.
2-Purchases by all Alliance Funds may not exceed the greater of (i) 4% of
the principal amount of the offering or (ii) $500,000 in principal amount,
but in no event may exeed 10% of the principal amount of the offering.
<PAGE>

                                                                    EXHIBIT 31.1

                  CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
                           PURSUANT TO RULE 13a-14(a)

     I, Gary D. Blackford, certify that:

     1. I have reviewed this quarterly report on Form 10-Q of Universal Hospital
Services, Inc.; and

     2. Based on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were
made, not misleading with respect to the period covered by this report.

     3. [intentionally omitted]

     4. [intentionally omitted]

     5. [intentionally omitted]

Date: April 7, 2004

                                      /s/ Gary D. Blackford
                                      ------------------------------------------
                                      Gary D. Blackford
                                      President and Chief Executive Officer
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM UNAUDITED
INTERIM STATEMENTS FOR THE THREE MONTHS ENDED JUNE 30, 1997 AND IS QUALIFIED IN
ITS ENTIRETY BY REFERENCE TO QUARTERLY REPORT ON FORM 10-QSB FOR THE QUARTERLY
PERIOD ENDED JUNE 30, 1997.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-1998
<PERIOD-START>                             APR-01-1997
<PERIOD-END>                               JUN-30-1997
<CASH>                                         332,998
<SECURITIES>                                         0
<RECEIVABLES>                                  214,352
<ALLOWANCES>                                    36,330
<INVENTORY>                                  1,605,208
<CURRENT-ASSETS>                             2,118,686
<PP&E>                                         423,618
<DEPRECIATION>                                 240,460
<TOTAL-ASSETS>                               2,342,051
<CURRENT-LIABILITIES>                        1,965,954
<BONDS>                                        500,000
<COMMON>                                        34,060
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                    (157,963)
<TOTAL-LIABILITY-AND-EQUITY>                 2,342,051
<SALES>                                        162,208
<TOTAL-REVENUES>                               389,059
<CGS>                                          154,900
<TOTAL-COSTS>                                  297,428
<OTHER-EXPENSES>                               372,729
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               7,490
<INCOME-PRETAX>                               (134,173)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (134,173)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (134,173)
<EPS-PRIMARY>                                    (0.01)
<EPS-DILUTED>                                    (0.01)
        

</TABLE>
## United States Court of Ap peals for the Federal Circuit

June 30, 2006

ERRATA

Appeal No. 05-1412

Bruckelmyer v. Ground Heaters

Decided: June 28, 2006 . Precedential

In Judge Newman's dissenting opinion from the denial of the petition for rehearing

en banc, the followin g change is made:

At page 2, third line from th e bottom of the slip opinion, after "printed publication

in" insert -- this or --.
<PAGE>

THE FOLLOWING STATEMENT IS BEING MADE TO THE SECURITIES AND EXCHANGE COMMISSION
SOLELY FOR PURPOSES OF SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C.
1350), WHICH CARRIES WITH IT CERTAIN CRIMINAL PENALTIES IN THE EVENT OF A
KNOWING OR WILLFUL MISREPRESENTATION.

Securities and Exchange Commission
450 Fifth Street, NW
Washington, DC  20549

      Re: Nuveen Investments, Inc.

Ladies and Gentlemen:

      In connection with the Quarterly Report on Form 10-Q for the period ending
September 30, 2004, as filed with the Securities and Exchange Commission (the
"Report") of Nuveen Investments, Inc. (the "Company") and pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, the undersigned hereby certifies that:

            (i) the Report fully complies with the requirements of section 13(a)
      or 15(d) of the Securities Exchange Act of 1934; and

            (ii) the information contained in the Report fairly presents, in all
      material respects, the financial condition and results of operations of
      the Company.

Dated as of this 5th day of November 2004.

                                              /s/ Timothy R. Schwertfeger
                                             --------------------------------
                                             Timothy R. Schwertfeger
                                             Chief Executive Officer
[Federal Register Volume 82, Number 162 (Wednesday, August 23, 2017)]
[Notices]
[Page 40013]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-17789]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the Center for 
Scientific Review Advisory Council.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Center for Scientific Review Advisory 
Council.
    Date: September 25, 2017.
    Time: 7:30 a.m. to 3:30 p.m.
    Agenda: Provide advice to the Director, Center for Scientific 
Review (CSR), on matters related to planning, execution, conduct, 
support, review, evaluation, and receipt and referral of grant 
applications at CSR.
    Place: National Institutes of Health, Third Floor Conference 
Center, 6701 Rockledge Drive, Bethesda, MD 20892.
    Contact Person: Rene Etcheberrigaray, MD, Deputy Director, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 3030, MSC 7776, Bethesda, MD 20892, (301) 435-
1111, <a href="/cdn-cgi/l/email-protection#2e4b5a4d464b4c4b5c6e4d5d5c0040474600494158"><span class="__cf_email__" data-cfemail="debbaabdb6bbbcbbac9ebdadacf0b0b7b6f0b9b1a8">[email protected]</span></a>.

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance into NIH buildings. Visitors will be asked 
to show one form of identification (for example, a government-issued 
photo ID, driver's license, or passport) and to state the purpose of 
their visit.
    Information is also available on the Institute's/Center's home 
page: http://public.csr.nih.gov/aboutcsr/CSROrganization/Pages/CSRAC.aspx, where an agenda and any additional information for the 
meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: August 17, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy..
[FR Doc. 2017-17789 Filed 8-22-17; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>